


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	12.17
Trade Time:	4:00 PM ET May 25, 2018
Change:	0.44  (3.751%)
Day Range	11.64 - 12.33
52-Week Range	9.83 - 25.22
Volume	632,410

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 24, 2018

[Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting](#)

May 4, 2018

[Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update](#)

May 2, 2018

[Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections](#)

May 2, 2018

[Achaogen Stock Trading Halted Today](#)

Apr 26, 2018

[Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 27, 2018

[Annual Report \(10-K\)](#)

Apr 18, 2018

[Proxy Statement \(DEF 14A\)](#)

May 7, 2018

[Quarterly Report \(10-Q\)](#)

Nov 8, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)